Lilly dropping Hanmi's BTK inhibitor

Eli Lilly and Co. (NYSE:LLY) discontinued from its pipeline a Bruton's tyrosine kinase (Btk) inhibitor it had licensed from Hanmi Pharmaceutical Co. Ltd. (KSE:128940). The pharma announced the pipeline update in its 4Q18 earnings presentation on Feb. 6. Lilly and Hanmi did not respond to inquiries regarding whether Lilly returned rights to the compound...